A LinkedIn post from C Ray Therapeutics describes a strategic partnership with SHINE Technologies focused on exclusive distribution of no-carrier-added Lu-177 in mainland China. The post indicates that C-Ray plans to source n.c.a. Lu-177 from SHINE’s Cassiopeia facility, described as one of North America’s largest dedicated production sites for this isotope.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, C-Ray intends to supply this Lu-177 to Chinese radiopharmaceutical developers, biotech companies, and healthcare institutions. The company also highlights downstream capabilities at its 28,000-square-meter Chengdu facility, including isotope conjugation, fill-and-finish, and quality control services, positioning the offering as an end-to-end isotope solution.
The post notes that C-Ray currently supports more than 30 radioisotopes across over 70 delivered projects, spanning IND-enabling work through Phase III clinical supply. For investors, this partnership and service footprint suggest an effort to strengthen C-Ray’s role as a contract development and manufacturing organization in the radiopharmaceutical supply chain, particularly within the growing Chinese market.
If execution aligns with the capabilities described, the arrangement could enhance recurring revenue potential from Lu-177 supply and value-added services. It may also improve C-Ray’s competitive position in radioligand therapy infrastructure, while providing SHINE with an established channel into China’s radiopharmaceutical ecosystem and associated clinical development activity.